June 14, 2024
The failure of “safe supply” was predictable. Purdue Pharma’s OxyContin helped start the addiction crisis, and Dilaudid, which is also manufactured by Purdue, is an even stronger and more addictive opioid.

‘Safe supply’ has only worsened the addiction crisis in London, Ont.

I have been a practicing physician in Ontario for 39 years, the last 16 of which have been in London. I have served in many capacities, including having a family practice and working as an acting medical officer of health. Since 2012, I have worked in addiction medicine. I feel compelled to speak out about the harm “safe supply” is causing in my community.

London is home to Canada’s first “safe supply” program that started at London InterCommunity Health Centre in 2016. It was, in part, a response to a public health emergency of tricuspid valve endocarditis, HIV and hepatitis C related to the injection of hydromorphone capsules. The goal was to provide high-risk sex workers using these hydromorphone capsules with an alternative: short-acting hydromorphone tablets, also known as Dilaudid.

I lived close to the health centre, and I initially supported the program. We did not have a problem with illicit fentanyl at the time.


See Also:

Doctors challenge evidence of “safer supply” fentanyl harm mitigation


Notify of
Inline Feedbacks
View all comments